Leading the way in
A CLEVER APPROACH TO FIGHT CANCER
Faron Pharmaceuticals Ltd (AIM: FARN, First North: FARON) is a global, clinical-stage biopharmaceutical company, focused on creating innovative cancer treatments that leverage the patient’s own immune system. We aim to address unmet medical needs in cancer and improve patient lives.
Introducing Faron
The Company’s lead asset bexmarilimab is currently being investigated in Phase I/II clinical trial as a potential therapy for patients with hematological cancers in combination with other standard treatments.
Bexmarilimab is a first-in-class anti-Clever-1 antibody and one of the most advanced myeloid cell-targeting immunotherapy candidates in clinical development.
In combination with standard-of-care, and in both solid tumors and hematologic malignancies, bexmarilimab may improve the efficacy of current cancer treatments and bring the promise of immunotherapy to a broader population.
We continue to see impressive growth in our bexmarilimab program, with exciting early data across both hematologic malignancies and solid tumors. These accomplishments could not have been done without the continued support of our shareholders and the incredible team at Faron. We have a bright future ahead and I’d like to thank everyone for their dedication to fighting cancer and improving patient outcomes.
DR. JUHO JALKANEN, MSCI, M.D., PH.D.
Chief Executive Officer & Founder
A rewarding career
Faron is on a mission to bring the promise of immunotherapy to a broader population. We are looking at new therapeutic approaches and novel combination therapies that could break treatment resistance and bring longer-lasting therapeutic outcomes to a greater proportion of patients.
We are a pioneer in macrophage-targeting therapies and have a novel pipeline that originates from academic discoveries and scientific findings. Faron offers a compelling career where brave thinkers and independent doers are joined.